Show simple item record

dc.contributor.authorWard, Timothy H
dc.contributor.authorButler, John
dc.contributor.authorShahbakhti, H
dc.contributor.authorRichards, J T
dc.date.accessioned2010-03-24T15:56:03Z
dc.date.available2010-03-24T15:56:03Z
dc.date.issued1997-04-25
dc.identifier.citationComet assay studies on the activation of two diaziridinylbenzoquinones in K562 cells. 1997, 53 (8):1115-21 Biochem. Pharmacol.en
dc.identifier.issn0006-2952
dc.identifier.pmid9175716
dc.identifier.urihttp://hdl.handle.net/10541/94925
dc.description.abstractTwo versions of the comet assay have been used to identify the difference in the modes of action of AZQ (2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone) and BZQ (2,5-diaziridinyl-3,6-bis(ethanolamino)-1,4-benzoquinone) in human leukaemia K562 cells and a K562-derived resistant cell line, BZQR. Using the standard alkaline assay, AZQ produced dose-dependent changes in the mean comet moments from K562 cells, consistent with the formation of strand breaks. This damage was repaired over a period of 6 hr after removal of the drug. The resistant cell line, BZQR, showed much smaller changes in comet moment under identical conditions. In contrast to AZQ, BZQ did not produce any measurable strand breaks in the K562 or BZQR cells. However, the comet radiation/crosslinking assay and a fluorescence-based assay revealed that BZQ extensively cross-links DNA in K562 cells. The extent of cross-linking is greatly reduced in the resistant cell line.
dc.language.isoenen
dc.subjectCultured Tumour Cellsen
dc.subject.meshAntineoplastic Agents
dc.subject.meshAziridines
dc.subject.meshBenzoquinones
dc.subject.meshCross-Linking Reagents
dc.subject.meshDNA Damage
dc.subject.meshDNA Repair
dc.subject.meshDrug Resistance
dc.subject.meshElectrophoresis, Agar Gel
dc.subject.meshHumans
dc.subject.meshTumor Cells, Cultured
dc.titleComet assay studies on the activation of two diaziridinylbenzoquinones in K562 cells.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Cell Culture, Paterson Institute for Cancer Research, Christie Hospital, Manchester, U.K.en
dc.identifier.journalBiochemical Pharmacologyen
html.description.abstractTwo versions of the comet assay have been used to identify the difference in the modes of action of AZQ (2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone) and BZQ (2,5-diaziridinyl-3,6-bis(ethanolamino)-1,4-benzoquinone) in human leukaemia K562 cells and a K562-derived resistant cell line, BZQR. Using the standard alkaline assay, AZQ produced dose-dependent changes in the mean comet moments from K562 cells, consistent with the formation of strand breaks. This damage was repaired over a period of 6 hr after removal of the drug. The resistant cell line, BZQR, showed much smaller changes in comet moment under identical conditions. In contrast to AZQ, BZQ did not produce any measurable strand breaks in the K562 or BZQR cells. However, the comet radiation/crosslinking assay and a fluorescence-based assay revealed that BZQ extensively cross-links DNA in K562 cells. The extent of cross-linking is greatly reduced in the resistant cell line.


This item appears in the following Collection(s)

Show simple item record